Novartis touts Lucentis studies; FDA won't enforce Swiss pharma's execution-drug recall;

 @FiercePharma: Here's Glaxo's take on the official launch of hostile HGS bid. Release | Follow @FiercePharma

> Under pressure on pricing of its eye drug Lucentis, Novartis ($NVS) touted new studies showing the treatment delivered long-lasting vision improvements in macular degeneration and diabetic macular edema patients. Report

> Swiss drugmaker Naari recalled the sodium thiopental held by the state of Nebraska, saying it was "illegally diverted" from the company's supply chain, but the state refuses to comply, and FDA says it won't force its hand. More

> L'Oreal lost its bid to hang onto its Botocyl and Botolist trademarks after a court determined they took "unfair advantage" of the fame of Allergan's ($AGN) Botox treatment. Story

> The FDA's review of bisphosphonate safety hit the New England Journal of Medicine, highlighting the risks of long-term use of common bone drugs such as Merck's ($MRK) Fosamax, Novartis' ($NVS) Reclast and Roche's ($RHHBY) Boniva. Report

> Bayer claims that India's Cipla stepped on its Nexavar patent rights by cutting the price of its generic version of the on-patent drug. News

> German genericsmaker Stada saw a 35% drop in net income, on charges related to its ongoing cost-cutting program. Article

Biotech News

 @FierceBiotech: First "cross-kingdom" vaccine effective in Phase I. Report | Follow @FierceBiotech

 @RyanMFierce: Check out Mark Leuchtenberger's scheduled IPO for Rib-X, an antibiotics developer, after price cut. More | Follow @RyanMFierce

> Biotech 'gambler' Blech loses big in securities scam. Story

> Subpar clinical trials probed in India's review of regulation. More

> Biotech startup Egalet lassos $14.3M B round, new CEO. Article

> FDA advisers sign off on Pfizer's arthritis pill. News

Medical Devices News

 @FierceMedDev: Finland's ArcDia grabs $3.5M in new financing to fuel growth of its respiratory infection diagnostic test. Item | Follow @FierceMedDev

> FDA looks to reduce kids' radiation exposure in draft guidance. News

> George Will jumps on the anti-device tax bandwagon. Article

> Report: Bad lifestyles fuel diagnostics boom in emerging markets. Story

> Study: Worriers, negative folks fair worse with ICDs. Report

Pharma Manufacturing News

 @EricPFierce: Ranbaxy's stellar first quarter shows the upside of having pharma manufacturing operations tip top. Report | Follow @EricPFierce

> 12-year-old consent decree lifted from Abbott. Story

> FDA critical of Genentech's Avastin production. Article

> Pfizer may announce $129M expansion in Belgium. More

> Patheon exiting most manufacturing at U.K. plant. Item

CRO News

 @NesaNFierce: Monkey see, monkey ... don't. MPI Research is getting lots of flack from the USDA and an animal rights group over animal mistreatment. Article | Follow @NesaNFierce

> CMO service pacts needed for success, Baxter says. News

> Kythera seeks $250,000 from Cetero for development delays. Story

> AMRI sees Q1 drops, but maintains positive financial outlook for 2012. More

> Covance sees early development losses, closes Arizona lab. Item

Vaccines News

> MMR and autism: Italy's courts get involved. Report

> Study: Further insight into Merck HIV vax infection increase. Article

> Pneumococcal vax cuts deaths, but cases tripled. News

> Swine flu vax could offer universal flu protection. Story

And Finally... Scientists find that dopamine helps us remember--and makes us forget. Report